Can-Fite Biopharma Profit Margin

As of the most recent data (June 2026), CANF shows a profit margin of -2358.77%. That compares with -1571.07% in the prior-year period — down 50.1% year over year. That is below the Healthcare sector average of 21.34%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CANF's profit margin is now -2358.77% (was -1571.07%) — a 50.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Can-Fite Biopharma is outperforming or lagging.

The Healthcare sector average profit margin is about 21.34%. Can-Fite Biopharma is at -2358.77%, which is lower that average. That is roughly 11155.7% below the sector mean. Use the comparison chart on this page to see how CANF stacks up against individual peers as well.

That compares with -1571.07% in the prior-year period — down 50.1% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Can-Fite Biopharma with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Can-Fite Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -2358.77%) with ownership activity and broader fundamentals.